64 stories
Foundayo is Eli Lilly's brand name for orforglipron, the first small-molecule GLP-1 pill approved for obesity. The FDA cleared it in early April 2026; the IQVIA launch tracker has stepped up from 3,707 prescriptions in Week 2 to 5,612 in Week 3 to 7,335 in Week 4 (the week ending May 1, per Citi's May 8 client note). Citi flagged that the IQVIA data captures retail and partial telehealth, likely understating Lilly Direct and the 12+ telehealth firms that account for roughly 35% of launch volume — Lilly executives have cited 20,000 patients now on the drug. Citi modeled $146M in Q2 and $1.6B for full-year 2026. On the April 30 Q1 call, Lilly disclosed more than 8,000 prescribers (one-third writing an oral GLP-1 for the first time) and 80% of patients new to the GLP-1 class — with commercial access confirmed at two of the three largest US PBMs effective mid-May.
The ACHIEVE-3 obesity Phase 3 gave Foundayo HbA1c superiority versus oral semaglutide in type-2 diabetes, but indirect comparisons published just after launch suggested oral Wegovy may produce greater weight loss with fewer GI discontinuations. Managed Healthcare Executive's head-to-head writeup framed the choice as HbA1c lead versus weight-loss lead. On May 4, an FAERS hepatic-failure case in a 56-year-old male — logged April 30 — surfaced publicly. LLY fell 3% premarket before recovering as Lilly released updated safety data the FDA had requested, citing no DILI signal across the 11,000-patient ACHIEVE+ATTAIN program. RBC Capital framed the case as 'baseline noise' and pointed to comparable hepatic-failure tallies for Mounjaro (30), Ozempic (33), Wegovy (15), and Zepbound (2).
The first full commercial quarter view landed on the Eli Lilly Q2 2026 earnings call Wednesday August 5, 2026 with Foundayo generating $98 million in revenue during its first fully operational quarter, providing the first commercial-earnings-line view of the oral small-molecule GLP-1 category. Lilly's combined obesity/diabetes franchise (Mounjaro + Zepbound + Foundayo) reached $14.9 billion in the quarter with LLY shares rising approximately 4% intraday on the earnings and guidance beat.
Stories here cover prescription volumes, payer coverage, head-to-head comparisons with oral Wegovy, and side-effect signals from FAERS. See [[orforglipron]] for the underlying molecule and [[oral-glp-1]] for class context.
Eli Lilly's Foundayo (orforglipron) won FDA approval with aggressive pricing as low as $25/month with savings card. Medicare Part D coverage could bring costs to $50/month starting July 2026.
Orforglipron (Foundayo) is the first GLP-1 pill that can be taken at any time without food or water restrictions, a major differentiator from oral semaglutide which requires morning dosing on an empty stomach.
Published the day after Foundayo's FDA approval, a new indirect comparison found oral semaglutide may produce greater weight loss than orforglipron with fewer GI discontinuations.
Managed Healthcare Executive compares Foundayo (orforglipron) vs oral Wegovy (semaglutide). ACHIEVE-3 trial data showed Foundayo superior on HbA1c, but oral Wegovy may edge ahead on weight loss.
In-depth comparison of Foundayo against existing GLP-1 drugs, noting 27 lbs average weight loss over 72 weeks at the highest dose. Experts hope more oral options will drive down costs and offer patients greater flexibility versus injectable regimens.
Foundayo became the first new molecular entity cleared under the Commissioner's National Priority Voucher Program, with review completed 294 days before the PDUFA date. Commercial pricing set at $25/month insured and $149/month self-pay at the lowest dose.
BioSpace reports Lilly launched Foundayo with $1.5 billion in pre-built inventory. Available via LillyDirect with prescriptions accepted immediately and shipping beginning April 6.
NBC News covers Foundayo's approval with self-pay pricing from $149-$349/month across six dose tiers. Medicare coverage for some patients could begin as early as summer 2026 with copays as low as $50/month.
The FDA approved Foundayo, a once-daily oral GLP-1 pill that can be taken any time without food or water restrictions. In trials, patients lost an average of 11% body weight over one year. It was approved under the FDA's National Priority Voucher program.
Foundayo's small-molecule design is easier to manufacture with fewer dosing restrictions than Novo Nordisk's peptide-based oral Wegovy. Analysts project Lilly's combined franchise could exceed $100 billion in peak revenue.